New imaging technique developed in Oxford could improve endometriosis diagnosis
Research aims to significantly reduce diagnosis waiting times
A new imaging technique, developed by researchers in Oxford, is showing promise in reducing the lengthy wait times for endometriosis diagnosis.
The technique, which utilises a molecular tracer known as maraciclatide, aims to help doctors identify the condition by detecting new blood vessel growth and inflammation within the body.
The average time from initial consultation to an official diagnosis of endometriosis in the UK is estimated to be over nine years, largely due to its symptoms that often mimic those of other conditions like IBS.
Endometriosis affects women when cells similar to those in the lining of the womb grow in other parts of the body. This can lead to severe discomfort, heavy periods, exhaustion, and pain during various activities.
Currently, diagnosis often involves multiple invasive tests, including vaginal exams, ultrasounds, MRI scans, and laparoscopies.
The Detect trial, conducted by Serac Healthcare and the Nuffield Department of Women’s & Reproductive Health at the University of Oxford, involved 20 women. Of these, 17 underwent a SPECT-CT scan followed by a laparoscopy.
The study successfully identified the presence or absence of endometriosis in 84% of participants and effectively provided detailed images of the condition in most cases validated by surgery.
Professor Christian Becker from Oxford, highlighted the importance of this non-invasive diagnostic method, stating that current techniques are limited and globally, novel tests are a research priority.
Further studies are necessary to confirm these promising results. Dr Tatjana Gibbons from Oxford noted that maraciclatide presents a promising tool for diagnosing and monitoring types of endometriosis, particularly the elusive superficial peritoneal variant.
The team expressed gratitude towards the participants of the Detect study, emphasising that without their involvement, such investigative strides would not be possible.
Professor Krina Zondervan also flagged the potential of maraciclatide to significantly improve clinical practise and research, with encouraging prospects for new treatment development if larger phase three studies replicate these findings.